

Krakow, 13<sup>th</sup> January 2025

## REQUEST FOR QUOTATION No. ABM- 13 01 2025 A

In connection with the implementation by Ryvu Therapeutics S.A. of the project ‘The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent’ (the ‘Project’) under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds ABM/2022/6 organized by the Medical Research Agency, Ryvu Therapeutics S.A. invites quotes for the execution of the following defined order description.

### I. ORDERING PARTY

Ryvu Therapeutics S.A.  
 Sternbacha 2, 30-394 Krakow, Poland  
 EU VAT PL6792942955

### II. ORDER DESCRIPTION

In the scope of the order description is the sale and delivery of the following products:

#### Part 1

No.	Name and Description	Package size	Quantity
1.	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: M5 - gender: male - race: white - age: above 65 - blast source: bone marrow - cell viability: min. 80 %	1 ml	1
2.	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: FAB M2 - gender: male - race: white - age: above 75 - blast source: bone marrow - cell viability: min. 85 %	1 ml	1
3.	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: M4 - gender: male - race: white - age: above 60 - blast source: bone marrow - cell viability: min. 60 %	1 ml	1

4.	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: M2 - gender: male - race: white - age: above 70 - blast source: bone marrow - cell viability: min. 90 %	1 ml	1
5.	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: M5 - gender: female - race: white - age: above 70 - blast source: bone marrow - cell viability: min. 80 %	1 ml	1
	Peripheral Blood Mononuclear Cells from patient - with leukemia, acute myeloid (AML) as primary diagnosis - overall clinical stage: FAB M4 - gender: male - race: white - age: above 50 - blast source: bone marrow - cell viability: min. 90 %	1 ml	1

- Offers submitted for products in packaging sizes other than those indicated above will be rejected.
- Rules of order execution:
  - Place of delivery - the seat of the Ordering Party.
  - Delivery date – up to 14 calendar days from the date of delivery of the order; If range of time given, the upper value will be considered; Offers indicating a longer period will be rejected.

### III. PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- III.1.** The offer must be submitted by: **20<sup>th</sup> January 2025 at 23.59 CET.**
- III.2.** The offer must be sent via e-mail to the following address: [tenders@ryvu.com](mailto:tenders@ryvu.com). The message with the offer should refer to the RFQ number indicated on the first page: **AMB-13 01 2025 A.**
- III.3.** The offer and its attachments should be prepared in Polish or English.
- III.4.** The quote should include the validity period (minimum 28 calendar days from the date of submission). The Ordering Party may require Bidders to agree to an extension of the quote validity period for the period of up to next 30 calendar days.

### IV. CRITERIA FOR EVALUATION OF QUOTES

- IV.1.** Offers that comply with the order description (set out in section II.) will be accepted for the evaluation of offers. Offers that do not meet the requirements will be rejected.
- IV.2.** Criterion: Net price ("C") – weight: 100% (10 points)
- IV.3.** Net price ("C") is considered as the total price for the execution of the order (purchase and delivery).
- IV.4.** Due to the possibility of submitting offers in parts, the Ordering Party allows more than one offer to be selected.
- IV.5.** As regards prices quoted in foreign currencies, in order to compare the offers they shall be converted into PLN at the average exchange rate of the National Bank of Poland (NBP) prevailing on the day of closing the tender procedure indicated in section IV.1.
- IV.6.** In the Net Price criterion, points will be awarded (to two decimal places) according to the formula:
- $$\text{Criterion Net price "C"} = \frac{\text{the lowest net price offered among the bids submitted}}{\text{net price of the examined offer}} \times 10 \text{ points}$$
- IV.7.** The Ordering Party will select as the most advantageous the offer that obtains the highest number of point.
- IV.8.** Having to choose between quotation scored in the same number of points, the Ordering Party will call Bidders to re-present the prices.

**V. ADDITIONAL INFORMATION**

- V.1.** The Bidders may ask the Ordering Party to clarify the content of this Quote Request. If the request for clarification of the content of the RFQ was received later than by the end of 15<sup>th</sup> January 2025, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: [tenders@ryvu.com](mailto:tenders@ryvu.com).
- V.2.** The Ordering Party reserves the right to change the content of the RFQ, including changes in the terms of the procedure. Bidders will be informed.
- V.3.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.
- V.4.** The Ordering Party reserves the right to close the procedure without selecting any of the offers or to cancel the procedure at any stage.
- V.5.** This RFQ does not oblige the Ordering Party to conclude a contract.
- V.6.** For more information, please contact Aleksandra Broda at the following email address: [tenders@ryvu.com](mailto:tenders@ryvu.com).